X
ELVN icon

Xponance’s Enliven Therapeutics ELVN Stock Holding History

Xponance’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$214K Buy
+4,225
New +$179K ﹤0.01% 1578

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Xponance's ELVN Position: Q2 2026 in Review

Xponance opened a new position in Enliven Therapeutics (ELVN) in Q2 2026: 4,225 shares worth $214K. The stake represents ﹤0.01% of the portfolio and ranks #1578 among its holdings.

210 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Xponance held 4,225 shares of Enliven Therapeutics worth $214K as of Q2 2026.
  • Enliven Therapeutics was a new Xponance position in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1578 holding.
  • 210 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.